Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction
Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction
复制标题
DOI：
10.1007/s11010-014-2089-0
复制
发表时间：
2014-09-01
影响因子：
4.3
通讯作者：
Dong, Shuling
中科院分区：
文献类型：
--
作者：
He, Fucheng;Lv, Pin;Dong, Shuling
MicroRNA（miRNAs）被证明存在于人类血液中，并且越来越多地被认为是心脏中各种病理过程的新生物标志物，包括心肌梗死、心肌重塑和心力衰竭的进展。在这项研究中，我们的目的是评估循环miR-328和miR-134在急性心肌梗死（AMI）患者中的诊断和预后价值。采用实时荧光定量PCR方法检测359例AMI患者和30例健康志愿者血浆中miR-328和miR-134的循环水平。使用基于电化学发光的方法测量高敏心肌肌钙蛋白T（hs-cTnT）的浓度。评估MiRNA对AMI临床诊断的区分以及与主要临床终点的关联，所述主要临床终点定义为梗死后6个月内心源性死亡和心力衰竭发展的复合终点。结果显示，AMI患者血浆miR-328和miR-134水平显著高于健康对照组。受试者工作特征曲线分析显示miR-328和miR-134对AMI具有显著的诊断价值。但两者在诊断上均上级hs-cTnT。此外，miR-328（OR 7.35，95%置信区间1.07-17.83，P < 0.001）和miR-134（OR 2.28，95%置信区间1.03-11.32，P < 0.001）的miRNA水平增加与6个月内死亡或心力衰竭风险增加密切相关。总之，循环中的miR-328和miR-134可能是AMI的潜在指标，并且miRNA水平与死亡或心力衰竭发展的风险增加相关。
MicroRNA (miRNAs) is demonstrated to be present in the blood of humans and has been increasingly suggested as a novel biomarker for various pathological processes in the heart, including myocardial infarction, myocardial remodeling and progression to heart failure. In this study, we aim to evaluate the diagnostic and prognostic value of circulating miR-328 and miR-134 in patients with acute myocardial infarction (AMI). Circulating levels of miR-328 and miR-134 were detected by quantitative real-time PCR in plasma samples from 359 AMI patients and 30 healthy volunteers. Concentrations of high-sensitivity cardiac troponin T (hs-cTnT) were measured using electrochemiluminescence-based methods. MiRNAs were assessed for discrimination of a clinical diagnosis of AMI and for association with primary clinical endpoint defined as a composite of cardiogenic death and development of heart failure within 6 months after infarction. Results showed that levels of plasma miR-328 and miR-134 were significantly higher in AMI patients than in healthy controls. Receiver operating characteristic curve analyses showed significant diagnostic value of miR-328 and miR-134 for AMI. However, neither of them was superior to hs-cTnT for the diagnosis. Additionally, increased miRNA levels were strongly associated with increased risk of mortality or heart failure within 6 months for miR-328 (OR 7.35, 95 % confidence interval 1.07-17.83, P < 0.001) and miR-134 (OR 2.28, 95 % confidence interval 1.03-11.32 P < 0.001). In conclusion, circulating miR-328 and miR-134 could be potential indicators for AMI, and the miRNA levels are associated with increased risk of mortality or development of heart failure.